ATE423852T1 - Methoden zur diagnose und prognose von krebs - Google Patents

Methoden zur diagnose und prognose von krebs

Info

Publication number
ATE423852T1
ATE423852T1 AT97920115T AT97920115T ATE423852T1 AT E423852 T1 ATE423852 T1 AT E423852T1 AT 97920115 T AT97920115 T AT 97920115T AT 97920115 T AT97920115 T AT 97920115T AT E423852 T1 ATE423852 T1 AT E423852T1
Authority
AT
Austria
Prior art keywords
cancer
methods
prb2
mutations
predict
Prior art date
Application number
AT97920115T
Other languages
English (en)
Inventor
Antonio Giordano
Alfonso Baldi
Original Assignee
Antonio Giordano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonio Giordano filed Critical Antonio Giordano
Application granted granted Critical
Publication of ATE423852T1 publication Critical patent/ATE423852T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97920115T 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs ATE423852T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1494396P 1996-04-05 1996-04-05
US1937296P 1996-06-05 1996-06-05
US2019696P 1996-06-21 1996-06-21
US3953297P 1997-03-03 1997-03-03

Publications (1)

Publication Number Publication Date
ATE423852T1 true ATE423852T1 (de) 2009-03-15

Family

ID=27486431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920115T ATE423852T1 (de) 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs

Country Status (7)

Country Link
EP (2) EP2014772A3 (de)
JP (2) JP2000510330A (de)
AT (1) ATE423852T1 (de)
AU (1) AU2438997A (de)
CA (1) CA2250854C (de)
DE (1) DE69739276D1 (de)
WO (1) WO1997038125A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002503108A (ja) * 1997-06-02 2002-01-29 トーマス ジェファーソン ユニバーシティ ｐＲｂ２／ｐ１３０を発現するベクターを使った癌細胞増殖を抑制する方法
US7737255B1 (en) 1998-09-02 2010-06-15 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating various cancers
US6261778B1 (en) * 1998-10-22 2001-07-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode SCP proteins, and uses thereof
WO2001094641A2 (en) * 2000-06-09 2001-12-13 Idec Pharmaceuticals Corporation Gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
ATE371191T1 (de) * 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
SG159547A1 (en) 2005-03-25 2010-03-30 Genentech Inc Methods and compositions for modulating hyperstabilized c-met
US20060263808A1 (en) * 2005-03-25 2006-11-23 Genentech, Inc. C-met mutations in lung cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341904B1 (de) 1988-05-09 1995-03-29 Temple University of the Commonwealth System of Higher Education Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten
EP0390530B1 (de) * 1989-03-31 1995-05-17 CANJI, Inc. Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen
US5234811A (en) * 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
WO1992015602A1 (en) * 1991-02-28 1992-09-17 Dana-Farber Cancer Institute, Inc. Cancer diagnosis and therapy
AU2178292A (en) * 1991-06-03 1993-01-08 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain
CA2096497A1 (en) * 1992-05-26 1993-11-27 Patricia Anne Spears Mycobacteria probes
WO1994011531A1 (en) * 1992-11-13 1994-05-26 California Institute Of Biological Research Identification of neoplasms by detection of genetic insertions and deletions
CA2167296C (en) * 1993-07-15 2002-02-19 Jay A. Tischfield Mammalian phospholipase a2 nucleotide sequences, low molecular weight amino acid sequences encoded thereby, antisense sequences and nucleotide sequences having internal ribosome binding sites
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit

Also Published As

Publication number Publication date
AU2438997A (en) 1997-10-29
EP2014772A2 (de) 2009-01-14
CA2250854A1 (en) 1997-10-16
EP0906448A4 (de) 2004-12-01
EP2014772A3 (de) 2009-05-27
EP2014772A8 (de) 2009-04-29
JP2008283985A (ja) 2008-11-27
EP0906448A1 (de) 1999-04-07
DE69739276D1 (de) 2009-04-09
EP0906448B1 (de) 2009-02-25
JP2000510330A (ja) 2000-08-15
WO1997038125A1 (en) 1997-10-16
CA2250854C (en) 2011-06-21

Similar Documents

Publication Publication Date Title
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
van Rens et al. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
ATE198623T1 (de) Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
WO2008084219A8 (en) Epigenetic change in selected genes and cancer
DE69929785D1 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
ATE423852T1 (de) Methoden zur diagnose und prognose von krebs
Elisei et al. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
Wollenberg et al. Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN
DE60036935D1 (de) Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
DE602004013554D1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes
ATE327766T1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
ATE442456T1 (de) Verfahren zur bestimmung von zirkulierender dns in plasma und zum nachweis von krebs
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
TW200517502A (en) Methods for detecting Alzheimer's disease
DE60309879D1 (de) Verfahren zur Diagnose von Krebs
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
ATE474935T1 (de) Verfahren und zusammensetzungen zur bestimmung von mutationen in nukleinsäure und deren verwendung in diagnose von genetischen krankheiten und krebs
EP1438326A4 (de) Diagnose, behandlung und prävention von krebs mit cables

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties